Behrenbruch Christian
Known title: MD & Group CEOCIK: 0002037713
Behrenbruch Christian's purchase track record
Behrenbruch Christian has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/28/2026 | TLX | $997K | -2.4% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TLX | ▲ Buy | Open Market | 33,435 | $497K | 4/29/2026 | View on chart |
| TLX | ▲ Buy | Open Market | 34,500 | $500K | 4/28/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Telix doses first US patients with FDA-approved Pixclara
Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.
Telix doses first US patients with FDA-approved Pixclara. Telix has begun dosing the first US patients with Pixclara, its FDA-approved imaging drug for glioma. The company also announced a partnership with Profound Medical to educate physicians on prostate cancer care and plans to host a Capital Markets Day in Melbourne in November 2026.